Melanoma Cancer Diagnostics Market Forecast, Trend Analysis & Competition Tracking: Global Market insights 2017 to 2022

  • Published : Jul-2017
  • Tables : 160
  • Figures : 54
  • Category : Healthcare
  • No. of Pages : 170
  • Report Code : FACT57MR
  • Format : ppt

Melanoma or malignant melanoma is a common type of skin cancer where melanocytes, cells containing pigments, begin to grow rapidly. Since occurrence of melanoma is restricted to skin, mouth, intestines or eyes, the diagnostics of melanoma comprises of multiple tests & screening methods such as excisional biopsy, lymph node status analysis, shave biopsy, and fine needle aspirate test.

The global melanoma cancer diagnostics market is projected to grow at a steady CAGR during the forecast period 2017-2027.

The melanoma cancer diagnostics market will be influenced by a combination of macroeconomic and microeconomic factors. Increasing spending on healthcare and advances in cancer detection and management are expected to contribute to the growth of the melanoma cancer diagnostics market. However, dearth of advanced solutions in developing countries will continue to pose growth challenges.

Market Taxonomy         

Test Type

End User

BRAF Mutation

Hospital Associated Labs

CTC

Independent Diagnostic Laboratories

Immunohistochemistry

Cancer Research Institutes

In Situ Hybridization

Others

Others

 

(Additional information, including cross-sectional data and country-wise analysis & forecast is available in the report)

Analysis by Test Type

By test type, the BRAF mutation test type segment will continue to be used widely for detecting the early onset of melanoma. In terms of revenue share, North America will account for majority share of revenues for the BRAF mutation segment globally. Use of BRAF mutation test type will also remain prevalent in Europe and APEJ.

The CTC segment will grow at a higher CAGR than BRAF mutation test type, with North America holding largest market share. However, it is the APEJ market where revenues will grow at the highest pace.

The immunohistochemistry segment of the global melanoma market is valued at over US$ 80 million in 2017. North America will remain the largest market for immunohistochemistry, followed by Europe and APEJ. Overall, the immunohistochemistry segment is projected to grow at a significant CAGR through 2022.

Analysis by End-Users

By end-users, the key segments of melanoma cancer diagnostics market include hospital associated labs, independent diagnostic laboratories, cancer research institutes, and ‘others’.

The hospital associated labs segment in North America is currently valued at over US$ 137 million, and is expected to grow at a steady CAGR through 2022. The hospital associated labs segment in Europe is anticipated to grow at a significant CAGR through 2022.

Independent diagnostic laboratories end-user segment in North America is expected to surpass US$ 100 million in revenues by 2022, growing at a high single-digit CAGR.

Region-wise Analysis

North America will remain an attractive market for global melanoma cancer diagnostic market. As discussed previously, BRAF mutation will remain the most widely used test type, followed by CTC. Hospital associated labs will continue to be the largest end-users in the North America melanoma cancer diagnostics market.

Europe, the second-largest market for melanoma cancer diagnostics, will continue to offer growth opportunities to manufacturers. By test type, the CTC cancer diagnostics market will continue to grow at highest CAGR, whereas hospital associated labs will be the largest end-users.

Overall, North America and Europe will continue to be the two most lucrative markets for melanoma cancer diagnostics globally.

Competition Tracking

The key companies profiled in the Fact.MR’s report on global melanoma cancer diagnostics market include Foundation Medicine, Inc., Cancer Genetics, Inc., Pathway Genomics Corporation, Abbott Laboratories, and Myriad Genetics Inc.

Note: The insights mentioned here are of the respective analysts, and do not reflect the position of Fact.MR

Chapter 1. Global Melanoma Cancer Diagnostics Market - Executive Summary. 20

Chapter 2. Global Melanoma Cancer Diagnostics Market Overview. 22
2.1. Introduction. 22
       2.1.1. Global Melanoma Cancer Diagnostics Market Taxonomy. 22
       2.1.2. Global Melanoma Cancer Diagnostics Market Definition. 22
2.2. Global Melanoma Cancer Diagnostics Market Size (US$ Mn) and Forecast, 2012-2022. 22
       2.2.1. Global Melanoma Cancer Diagnostics Market Y-o-Y Growth. 22
2.3. Global Melanoma Cancer Diagnostics Market Dynamics. 23
       2.3.1. Drivers. 23
       2.3.2. Restraints. 23
       2.3.3. Trends. 23
2.4. Supply Chain. 24
2.5. Epidemiology. 24
2.6. List of Distributors. 24
2.7. Average Pricing Analysis. 24
2.8. Regulations. 25
2.9. Key Participants Market Presence (Intensity Map) By Region. 25

Chapter 3. Global Melanoma Cancer Diagnostics Market Analysis and Forecast By Test Type. 26
3.1. Global Melanoma Cancer Diagnostics Market Size and Forecast By Test Type, 2012-2022. 26
       3.1.1. BRAF Mutation Melanoma Cancer Diagnostics Market Size and Forecast, 2012-2022. 26
                3.1.1.1. Revenue (US$ Mn) Comparison, By Region. 26
                3.1.1.2. Market Share Comparison, By Region. 28
3.1.1.3. Y-o-Y growth Comparison, By Region. 28
       3.1.2. CTC Melanoma Cancer Diagnostics Market Size and Forecast, 2012-2022. 29
                3.1.2.1. Revenue (US$ Mn) Comparison, By Region. 29
                3.1.2.2. Market Share Comparison, By Region. 31
                3.1.2.3. Y-o-Y growth Comparison, By Region. 31
       3.1.3. Immunohistochemistry Melanoma Cancer Diagnostics Market Size and Forecast, 2012-2022. 32
                3.1.3.1. Revenue (US$ Mn) Comparison, By Region. 32
                3.1.3.2. Market Share Comparison, By Region. 34
                3.1.3.3. Y-o-Y growth Comparison, By Region. 34
       3.1.4. In Situ Hybridization Melanoma Cancer Diagnostics Market Size and Forecast, 2012-2022. 35
                3.1.4.1. Revenue (US$ Mn) Comparison, By Region. 35
                3.1.4.2. Market Share Comparison, By Region. 37
                3.1.4.3. Y-o-Y growth Comparison, By Region. 37
       3.1.5. Others Melanoma Cancer Diagnostics Market Size and Forecast, 2012-2022. 38
                3.1.5.1. Revenue (US$ Mn) Comparison, By Region. 38
                3.1.5.2. Market Share Comparison, By Region. 40
                3.1.5.3. Y-o-Y growth Comparison, By Region. 40

Chapter 4. Global Melanoma Cancer Diagnostics Market Analysis and Forecast By End User. 42
4.1. Global Melanoma Cancer Diagnostics Market Size and Forecast By End User, 2012-2022. 42
       4.1.1. Hospital Associated Labs Melanoma Cancer Diagnostics Market Size and Forecast, 2012-2022. 42
                4.1.1.1. Revenue (US$ Mn) Comparison, By Region. 42
                4.1.1.2. Market Share Comparison, By Region. 44
                4.1.1.3. Y-o-Y growth Comparison, By Region. 44
       4.1.2. Independent Diagnostic Laboratories Melanoma Cancer Diagnostics Market Size and Forecast, 2012-2022. 45
                4.1.2.1. Revenue (US$ Mn) Comparison, By Region. 45
                4.1.2.2. Market Share Comparison, By Region. 47
                4.1.2.3. Y-o-Y growth Comparison, By Region. 47
       4.1.3. Cancer Research Institutes Melanoma Cancer Diagnostics Market Size and Forecast, 2012-2022. 48
                4.1.3.1. Revenue (US$ Mn) Comparison, By Region. 48
                4.1.3.2. Market Share Comparison, By Region. 50
                4.1.3.3. Y-o-Y growth Comparison, By Region. 50
       4.1.4. Others Melanoma Cancer Diagnostics Market Size and Forecast, 2012-2022. 51
                4.1.4.1. Revenue (US$ Mn) Comparison, By Region. 51
                4.1.4.2. Market Share Comparison, By Region. 53
                4.1.4.3. Y-o-Y growth Comparison, By Region. 53

Chapter 5. Global Melanoma Cancer Diagnostics Market Analysis and Forecast By Region. 55
5.1. Global Melanoma Cancer Diagnostics Market Size and Forecast, 2012-2022. 55
       5.1.1. North America Melanoma Cancer Diagnostics Market Size and Forecast, 2012-2022. 55
                5.1.1.1. Revenue (US$ Mn) Comparison, By Test Type. 55
                5.1.1.2. Revenue (US$ Mn) Comparison, By End User. 56
       5.1.2. Latin America Melanoma Cancer Diagnostics Market Size and Forecast, 2012-2022. 58
                5.1.2.1. Revenue (US$ Mn) Comparison, By Test Type. 58
                5.1.2.2. Revenue (US$ Mn) Comparison, By End User. 60
       5.1.3. Europe Melanoma Cancer Diagnostics Market Size and Forecast, 2012-2022. 61
                5.1.3.1. Revenue (US$ Mn) Comparison, By Test Type. 61
                5.1.3.2. Revenue (US$ Mn) Comparison, By End User. 63
       5.1.4. Japan Melanoma Cancer Diagnostics Market Size and Forecast, 2012-2022. 64
                5.1.4.1. Revenue (US$ Mn) Comparison, By Test Type. 64
                5.1.4.2. Revenue (US$ Mn) Comparison, By End User. 66
       5.1.5. APEJ Melanoma Cancer Diagnostics Market Size and Forecast, 2012-2022. 67
                5.1.5.1. Revenue (US$ Mn) Comparison, By Test Type. 67
                5.1.5.2. Revenue (US$ Mn) Comparison, By End User. 69
       5.1.6. MEA Melanoma Cancer Diagnostics Market Size and Forecast, 2012-2022. 70
                5.1.6.1. Revenue (US$ Mn) Comparison, By Test Type. 70
                5.1.6.2. Revenue (US$ Mn) Comparison, By End User. 72

Chapter 6. North America Melanoma Cancer Diagnostics Market Analysis and Forecast, By Country, 2012-2022. 74
6.1. US Melanoma Cancer Diagnostics Market Size and Forecast, 2012-2022. 74
       6.1.1. Revenue (US$ Mn) Comparison, By Test Type. 74
       6.1.2. Revenue (US$ Mn) Comparison, By End User. 75
6.2. Canada Melanoma Cancer Diagnostics Market Size and Forecast, 2012-2022. 76
       6.2.1. Revenue (US$ Mn) Comparison, By Test Type. 76
       6.2.2. Revenue (US$ Mn) Comparison, By End User. 77

Chapter 7. Latin America Melanoma Cancer Diagnostics Market Analysis and Forecast, By Country, 2012-2022. 78
7.1. Brazil Melanoma Cancer Diagnostics Market Size and Forecast, 2012-2022. 78
       7.1.1. Revenue (US$ Mn) Comparison, By Test Type. 78
       7.1.2. Revenue (US$ Mn) Comparison, By End User. 79
7.2. Mexico Melanoma Cancer Diagnostics Market Size and Forecast, 2012-2022. 80
       7.2.1. Revenue (US$ Mn) Comparison, By Test Type. 80
       7.2.2. Revenue (US$ Mn) Comparison, By End User. 81
7.3. Argentina Melanoma Cancer Diagnostics Market Size and Forecast, 2012-2022. 82
       7.3.1. Revenue (US$ Mn) Comparison, By Test Type. 82
       7.3.2. Revenue (US$ Mn) Comparison, By End User. 83

Chapter 8. Europe Melanoma Cancer Diagnostics Market Analysis and Forecast, By Country, 2012-2022. 84
8.1. Germany Melanoma Cancer Diagnostics Market Size and Forecast, 2012-2022. 84
       8.1.1. Revenue (US$ Mn) Comparison, By Test Type. 84
       8.1.2. Revenue (US$ Mn) Comparison, By End User. 85
8.2. UK Melanoma Cancer Diagnostics Market Size and Forecast, 2012-2022. 86
       8.2.1. Revenue (US$ Mn) Comparison, By Test Type. 86
       8.2.2. Revenue (US$ Mn) Comparison, By End User. 87
8.3. France Melanoma Cancer Diagnostics Market Size and Forecast, 2012-2022. 88
       8.3.1. Revenue (US$ Mn) Comparison, By Test Type. 88
       8.3.2. Revenue (US$ Mn) Comparison, By End User. 89
8.4. Spain Melanoma Cancer Diagnostics Market Size and Forecast, 2012-2022. 90
       8.4.1. Revenue (US$ Mn) Comparison, By Test Type. 90
       8.4.2. Revenue (US$ Mn) Comparison, By End User. 91
8.5. Italy Melanoma Cancer Diagnostics Market Size and Forecast, 2012-2022. 92
       8.5.1. Revenue (US$ Mn) Comparison, By Test Type. 92
       8.5.2. Revenue (US$ Mn) Comparison, By End User. 93
8.6. Nordic Melanoma Cancer Diagnostics Market Size and Forecast, 2012-2022. 94
       8.6.1. Revenue (US$ Mn) Comparison, By Test Type. 94
       8.6.2. Revenue (US$ Mn) Comparison, By End User. 95

Chapter 9. Japan Melanoma Cancer Diagnostics Market Analysis and Forecast, By Country, 2012-2022. 96
9.1. Japan  Melanoma Cancer Diagnostics Market Size and Forecast, 2012-2022. 96
       9.1.1. Revenue (US$ Mn) Comparison, By Test Type. 96
       9.1.2. Revenue (US$ Mn) Comparison, By End User. 97

Chapter 10. APEJ Melanoma Cancer Diagnostics Market Analysis and Forecast, By Country, 2012-2022. 98
10.1. China Melanoma Cancer Diagnostics Market Size and Forecast, 2012-2022. 98
       10.1.1. Revenue (US$ Mn) Comparison, By Test Type. 98
       10.1.2. Revenue (US$ Mn) Comparison, By End User. 99
10.2. India Melanoma Cancer Diagnostics Market Size and Forecast, 2012-2022. 100
       10.2.1. Revenue (US$ Mn) Comparison, By Test Type. 100
       10.2.2. Revenue (US$ Mn) Comparison, By End User. 101
10.3. Malaysia Melanoma Cancer Diagnostics Market Size and Forecast, 2012-2022. 102
       10.3.1. Revenue (US$ Mn) Comparison, By Test Type. 102
       10.3.2. Revenue (US$ Mn) Comparison, By End User. 103
10.4. Thailand Melanoma Cancer Diagnostics Market Size and Forecast, 2012-2022. 104
       10.4.1. Revenue (US$ Mn) Comparison, By Test Type. 104
       10.4.2. Revenue (US$ Mn) Comparison, By End User. 105
10.5. Singapore Melanoma Cancer Diagnostics Market Size and Forecast, 2012-2022. 106
       10.5.1. Revenue (US$ Mn) Comparison, By Test Type. 106
       10.5.2. Revenue (US$ Mn) Comparison, By End User. 107       
10.6. Australia Melanoma Cancer Diagnostics Market Size and Forecast, 2012-2022. 108
       10.6.1. Revenue (US$ Mn) Comparison, By Test Type. 108
       10.6.2. Revenue (US$ Mn) Comparison, By End User. 109

Chapter 11. MEA Melanoma Cancer Diagnostics Market Analysis and Forecast, By Country, 2012-2022. 110
11.1. GCC Countries Melanoma Cancer Diagnostics Market Size and Forecast, 2012-2022. 110
       11.1.1. Revenue (US$ Mn) Comparison, By Test Type. 110
       11.1.2. Revenue (US$ Mn) Comparison, By End User. 111
11.2. South Africa Melanoma Cancer Diagnostics Market Size and Forecast, 2012-2022. 112
       11.2.1. Revenue (US$ Mn) Comparison, By Test Type. 112
       11.2.2. Revenue (US$ Mn) Comparison, By End User. 113
11.3. Nigeria Melanoma Cancer Diagnostics Market Size and Forecast, 2012-2022. 114
       11.3.1. Revenue (US$ Mn) Comparison, By Test Type. 114
       11.3.2. Revenue (US$ Mn) Comparison, By End User. 115
11.4. Israel Melanoma Cancer Diagnostics Market Size and Forecast, 2012-2022. 116
       11.4.1. Revenue (US$ Mn) Comparison, By Test Type. 116
       11.4.2. Revenue (US$ Mn) Comparison, By End User. 117

Chapter 12. Company Profile. 118
12.1. Foundation Medicine, Inc.. 118
       12.1.1. Company Overview. 118
       12.1.2. Product Overview. 118
       12.1.3. Key Financials. 119
12.2. Cancer Genetics, Inc.. 120
       12.2.1. Company Overview. 120
       12.2.2. Product Overview. 120
       12.2.3. Key Financials. 121
       12.2.4. Key Developments. 121
12.3. Pathway Genomics Corporation. 122
       12.3.1. Company Overview. 122
       12.3.2. Product Overview. 122
12.4. Abbott Laboratories. 123
       12.4.1. Company Overview. 123
       12.4.2. Product Overview. 123
       12.4.3. Key Financials. 124
       12.4.4. Key Developments. 124
12.5. Myriad Genetics Inc.. 125
       12.5.1. Company Overview. 125
       12.5.2. Product Overview. 125
       12.5.3. Key Financials. 126
       12.5.4. SWOT Analysis. 126
12.6. Quest Diagnostics Incorporated. 128
       12.6.1. Company Overview. 128
       12.6.2. Product Overview. 128
       12.6.3. Key Financials. 128
       12.6.4. SWOT Analysis. 129
12.7. Roche Holding AG. 131
       12.7.1. Company Overview. 131
       12.7.2. Product Overview. 131
       12.7.3. Key Financials. 132
12.8. Agilent Technologies. 133
       12.8.1. Company Overview. 133
       12.8.2. Product Overview. 133
       12.8.3. Key Financials. 133
       12.8.4. Key Developments ". 133
       12.8.5. SWOT Analysis. 134
12.9. Thermo Fisher Scientific Inc.. 135
       12.9.1. Company Overview. 135
       12.9.2. Product Overview. 135
       12.9.3. Key Financials:. 136
       12.9.4. SWOT Analysis. 136
       12.9.5. Key Developments. 137
12.10. Bristol-Myers Squibb Company. 138
       12.10.1. Company Overview. 138
       12.10.2. Product Overview. 138
       12.10.3. Key Financials. 138
       12.10.4. Key Developments. 138
       12.10.5. SWOT Analysis. 139

Chapter 13. Disclaimer and Contact information. 143

TABLE 1 Global Melanoma Cancer Diagnostics Market Value (US$ Mn), 2012-2016 23
TABLE 2 Global Melanoma Cancer Diagnostics Market Value (US$ Mn), 2017-2022 24
TABLE 3 Global Melanoma Cancer Diagnostics Market Value (US$ Mn) and Y-o-Y, 2015-2022 25
TABLE 4 Global BRAF Mutation Segment Value (US$ Mn), By Region 2012-2016 29
TABLE 5 Global BRAF Mutation Segment Value (US$ Mn), By Region 2017-2022 30
TABLE 6 Global BRAF Mutation Segment Market Share, By Region 2012-2016 31
TABLE 7 Global BRAF Mutation Segment Market Share, By Region 2017-2022 31
TABLE 8 Global BRAF Mutation Segment Y-o-Y, By Region 2015-2022 31
TABLE 9 Global CTC Segment Value (US$ Mn), By Region 2012-2016 32
TABLE 10 Global CTC Segment Value (US$ Mn), By Region 2017-2022 33
TABLE 11 Global CTC Segment Market Share, By Region 2012-2016 34
TABLE 12 Global CTC Segment Market Share, By Region 2017-2022 34
TABLE 13 Global CTC Segment Y-o-Y, By Region 2015-2022 34
TABLE 14 Global Immunohistochemistry Segment Value (US$ Mn), By Region 2012-2016 35
TABLE 15 Global Immunohistochemistry Segment Value (US$ Mn), By Region 2017-2022 36
TABLE 16 Global Immunohistochemistry Segment Market Share, By Region 2012-2016 37
TABLE 17 Global Immunohistochemistry Segment Market Share, By Region 2017-2022 37
TABLE 18 Global Immunohistochemistry Segment Y-o-Y, By Region 2015-2022 37
TABLE 19 Global In Situ Hybridization  Segment Value (US$ Mn), By Region 2012-2016 38
TABLE 20 Global In Situ Hybridization  Segment Value (US$ Mn), By Region 2017-2022 39
TABLE 21 Global In Situ Hybridization  Segment Market Share, By Region 2012-2016 40
TABLE 22 Global In Situ Hybridization  Segment Market Share, By Region 2017-2022 40
TABLE 23 Global In Situ Hybridization  Segment Y-o-Y, By Region 2015-2022 40
TABLE 24 Global Others Segment Value (US$ Mn), By Region 2012-2016 41
TABLE 25 Global Others Segment Value (US$ Mn), By Region 2017-2022 42
TABLE 26 Global Others Segment Market Share, By Region 2012-2016 43
TABLE 27 Global Others Segment Market Share, By Region 2017-2022 43
TABLE 28 Global Others Segment Y-o-Y, By Region 2015-2022 43
TABLE 29 Global Hospital Associated Labs Segment Value (US$ Mn), By Region 2012-2016 45
TABLE 30 Global Hospital Associated Labs Segment Value (US$ Mn), By Region 2017-2022 46
TABLE 31 Global Hospital Associated Labs Segment Market Share, By Region 2012-2016 47
TABLE 32 Global Hospital Associated Labs Segment Market Share, By Region 2017-2022 47
TABLE 33 Global Hospital Associated Labs Segment Y-o-Y, By Region 2015-2022 47
TABLE 34 Global Independent Diagnostic Laboratories Segment Value (US$ Mn), By Region 2012-2016 48
TABLE 35 Global Independent Diagnostic Laboratories Segment Value (US$ Mn), By Region 2017-2022 49
TABLE 36 Global Independent Diagnostic Laboratories Segment Market Share, By Region 2012-2016 50
TABLE 37 Global Independent Diagnostic Laboratories Segment Market Share, By Region 2017-2022 50
TABLE 38 Global Independent Diagnostic Laboratories Segment Y-o-Y, By Region 2015-2022 50
TABLE 39 Global Cancer Research Institutes Segment Value (US$ Mn), By Region 2012-2016 51
TABLE 40 Global Cancer Research Institutes Segment Value (US$ Mn), By Region 2017-2022 52
TABLE 41 Global Cancer Research Institutes Segment Market Share, By Region 2012-2016 53
TABLE 42 Global Cancer Research Institutes Segment Market Share, By Region 2017-2022 53
TABLE 43 Global Cancer Research Institutes Segment Y-o-Y, By Region 2015-2022 53
TABLE 44 Global Others Segment Value (US$ Mn), By Region 2012-2016 54
TABLE 45 Global Others Segment Value (US$ Mn), By Region 2017-2022 55
TABLE 46 Global Others Segment Market Share, By Region 2012-2016 56
TABLE 47 Global Others Segment Market Share, By Region 2017-2022 56
TABLE 48 Global Others Segment Y-o-Y, By Region 2015-2022 56
TABLE 49 North America Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 58
TABLE 50 North America Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 58
TABLE 51 North America Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 59
TABLE 52 North America Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 60
TABLE 53 Latin America Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 61
TABLE 54 Latin America Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 62
TABLE 55 Latin America Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 63
TABLE 56 Latin America Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 63
TABLE 57 Europe Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 64
TABLE 58 Europe Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 65
TABLE 59 Europe Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 66
TABLE 60 Europe Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 66
TABLE 61 Japan Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 67
TABLE 62 Japan Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 68
TABLE 63 Japan Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 69
TABLE 64 Japan Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 69
TABLE 65 APEJ Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 70
TABLE 66 APEJ Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 71
TABLE 67 APEJ Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 72
TABLE 68 APEJ Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 72
TABLE 69 MEA Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 73
TABLE 70 MEA Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 74
TABLE 71 MEA Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 75
TABLE 72 MEA Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 75
TABLE 73 US Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 77
TABLE 74 US Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 77
TABLE 75 US Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 78
TABLE 76 US Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 78
TABLE 77 Canada Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 79
TABLE 78 Canada Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 79
TABLE 79 Canada Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 80
TABLE 80 Canada Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 80
TABLE 81 Brazil Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 81
TABLE 82 Brazil Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 81
TABLE 83 Brazil Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 82
TABLE 84 Brazil Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 82
TABLE 85 Mexico Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 83
TABLE 86 Mexico Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 83
TABLE 87 Mexico Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 84
TABLE 88 Mexico Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 84
TABLE 89 Argentina Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 85
TABLE 90 Argentina Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 85
TABLE 91 Argentina Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 86
TABLE 92 Argentina Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 86
TABLE 93 Germany Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 87
TABLE 94 Germany Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 87
TABLE 95 Germany Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 88
TABLE 96 Germany Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 88
TABLE 97 UK Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 89
TABLE 98 UK Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 89
TABLE 99 UK Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 90
TABLE 100 UK Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 90
TABLE 101 France Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 91
TABLE 102 France Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 91
TABLE 103 France Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 92
TABLE 104 France Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 92
TABLE 105 Spain Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 93
TABLE 106 Spain Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 93
TABLE 107 Spain Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 94
TABLE 108 Spain Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 94
TABLE 109 Italy Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 95
TABLE 110 Italy Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 95
TABLE 111 Italy Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 96
TABLE 112 Italy Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 96
TABLE 113 Nordic Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 97
TABLE 114 Nordic Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 97
TABLE 115 Nordic Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 98
TABLE 116 Nordic Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 98
TABLE 117 Japan  Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 99
TABLE 118 Japan  Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 99
TABLE 119 Japan  Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 100
TABLE 120 Japan  Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 100
TABLE 121 China Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 101
TABLE 122 China Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 101
TABLE 123 China Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 102
TABLE 124 China Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 102
TABLE 125 India Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 103
TABLE 126 India Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 103
TABLE 127 India Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 104
TABLE 128 India Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 104
TABLE 129 Malaysia Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 105
TABLE 130 Malaysia Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 105
TABLE 131 Malaysia Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 106
TABLE 132 Malaysia Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 106
TABLE 133 Thailand Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 107
TABLE 134 Thailand Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 107
TABLE 135 Thailand Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 108
TABLE 136 Thailand Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 108
TABLE 137 Singapore Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 109
TABLE 138 Singapore Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 109
TABLE 139 Singapore Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 110
TABLE 140 Singapore Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 110
TABLE 141 Australia Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 111
TABLE 142 Australia Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 111
TABLE 143 Australia Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 112
TABLE 144 Australia Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 112
TABLE 145 GCC Countries Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 113
TABLE 146 GCC Countries Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 113
TABLE 147 GCC Countries Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 114
TABLE 148 GCC Countries Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 114
TABLE 149 South Africa Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 115
TABLE 150 South Africa Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 115
TABLE 151 South Africa Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 116
TABLE 152 South Africa Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 116
TABLE 153 Nigeria Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 117
TABLE 154 Nigeria Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 117
TABLE 155 Nigeria Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 118
TABLE 156 Nigeria Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 118
TABLE 157 Israel Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 119
TABLE 158 Israel Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 119
TABLE 159 Israel Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 120
TABLE 160 Israel Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 120

FIG. 1 Global Melanoma Cancer Diagnostics Market Value (US$ Mn), 2012-2016 15
FIG. 2 Global Melanoma Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017-2022 15
FIG. 3 Global Melanoma Cancer Diagnostics Market Value (US$ Mn) and Y-o-Y, 2015-2022 17
FIG. 4 Global BRAF Mutation Segment Market Value (US$ Mn) By Region, 2012-2016 20
FIG. 5 Global BRAF Mutation Segment Market Value (US$ Mn) By Region, 2017-2022 21
FIG. 6 Global BRAF Mutation Segment Y-o-Y Growth Rate, By Region, 2015-2022 23
FIG. 7 Global CTC Segment Market Value (US$ Mn) By Region, 2012-2016 23
FIG. 8 Global CTC Segment Market Value (US$ Mn) By Region, 2017-2022 24
FIG. 9 Global CTC Segment Y-o-Y Growth Rate, By Region, 2015-2022 26
FIG. 10 Global Immunohistochemistry Segment Market Value (US$ Mn) By Region, 2012-2016 26
FIG. 11 Global Immunohistochemistry Segment Market Value (US$ Mn) By Region, 2017-2022 27
FIG. 12 Global Immunohistochemistry Segment Y-o-Y Growth Rate, By Region, 2015-2022 29
FIG. 13 Global In Situ Hybridization  Segment Market Value (US$ Mn) By Region, 2012-2016 29
FIG. 14 Global In Situ Hybridization  Segment Market Value (US$ Mn) By Region, 2017-2022 30
FIG. 15 Global In Situ Hybridization  Segment Y-o-Y Growth Rate, By Region, 2015-2022 32
FIG. 16 Global Others Segment Market Value (US$ Mn) By Region, 2012-2016 32
FIG. 17 Global Others Segment Market Value (US$ Mn) By Region, 2017-2022 33
FIG. 18 Global Others Segment Y-o-Y Growth Rate, By Region, 2015-2022 35
FIG. 19 Global Hospital Associated Labs Segment Market Value (US$ Mn) By Region, 2012-2016 36
FIG. 20 Global Hospital Associated Labs Segment Market Value (US$ Mn) By Region, 2017-2022 37
FIG. 21 Global Hospital Associated Labs Segment Y-o-Y Growth Rate, By Region, 2015-2022 39
FIG. 22 Global Independent Diagnostic Laboratories Segment Market Value (US$ Mn) By Region, 2012-2016 39
FIG. 23 Global Independent Diagnostic Laboratories Segment Market Value (US$ Mn) By Region, 2017-2022 40
FIG. 24 Global Independent Diagnostic Laboratories Segment Y-o-Y Growth Rate, By Region, 2015-2022 42
FIG. 25 Global Cancer Research Institutes Segment Market Value (US$ Mn) By Region, 2012-2016 42
FIG. 26 Global Cancer Research Institutes Segment Market Value (US$ Mn) By Region, 2017-2022 43
FIG. 27 Global Cancer Research Institutes Segment Y-o-Y Growth Rate, By Region, 2015-2022 45
FIG. 28 Global Others Segment Market Value (US$ Mn) By Region, 2012-2016 45
FIG. 29 Global Others Segment Market Value (US$ Mn) By Region, 2017-2022 46
FIG. 30 Global Others Segment Y-o-Y Growth Rate, By Region, 2015-2022 48
FIG. 31 North America Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 49
FIG. 32 North America Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 50
FIG. 33 North America Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 51
FIG. 34 North America Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 51
FIG. 35 Latin America Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 52
FIG. 36 Latin America Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 53
FIG. 37 Latin America Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 54
FIG. 38 Latin America Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 55
FIG. 39 Europe Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 56
FIG. 40 Europe Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 56
FIG. 41 Europe Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 57
FIG. 42 Europe Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 58
FIG. 43 Japan Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 59
FIG. 44 Japan Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 59
FIG. 45 Japan Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 60
FIG. 46 Japan Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 61
FIG. 47 APEJ Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 62
FIG. 48 APEJ Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 62
FIG. 49 APEJ Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 63
FIG. 50 APEJ Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 64
FIG. 51 MEA Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 65
FIG. 52 MEA Melanoma Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 65
FIG. 53 MEA Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 66
FIG. 54 MEA Melanoma Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 67

We are committed towards customer satisfaction and quality service.


Our Clients

Malaysian Cocoa Board
Dunlop International Europe Ltd
Roland Berger
Superior Essex
Commscope
Deloitte

Fact.MR in Media

Benefits of Becoming a Fact.MR Client

  • Access to our global market coverage
  • Periodic updates on your sector
  • Exclusive discounts and offers
  • Greater flexibility for customization
  • Quick-research assistance for ad-hoc needs
  • Access to credible insights Fact.MR analyst interactions
  • Access to Fact.MR tools and research to fuel strategy development